Keybank National Association OH Sells 3,736 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Keybank National Association OH trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 17.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,217 shares of the medical instruments supplier's stock after selling 3,736 shares during the quarter. Keybank National Association OH's holdings in West Pharmaceutical Services were worth $3,855,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Rossby Financial LCC purchased a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $219,000. DAVENPORT & Co LLC lifted its holdings in shares of West Pharmaceutical Services by 103.8% during the first quarter. DAVENPORT & Co LLC now owns 2,230 shares of the medical instruments supplier's stock valued at $499,000 after purchasing an additional 1,136 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of West Pharmaceutical Services by 0.7% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 7,887 shares of the medical instruments supplier's stock valued at $1,766,000 after purchasing an additional 57 shares during the last quarter. Rovin Capital UT ADV purchased a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $393,000. Finally, Amalgamated Bank lifted its holdings in shares of West Pharmaceutical Services by 1.0% during the first quarter. Amalgamated Bank now owns 14,749 shares of the medical instruments supplier's stock valued at $3,302,000 after purchasing an additional 145 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

NYSE:WST traded down $0.77 during trading hours on Monday, reaching $221.49. The company had a trading volume of 400,415 shares, compared to its average volume of 735,944. The company has a current ratio of 2.77, a quick ratio of 2.03 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $352.33. The firm has a market cap of $15.91 billion, a price-to-earnings ratio of 34.77, a PEG ratio of 5.47 and a beta of 1.09. The firm's 50 day moving average price is $215.93 and its 200-day moving average price is $247.95.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.23. West Pharmaceutical Services had a net margin of 16.13% and a return on equity of 18.23%. The business had revenue of $698.00 million during the quarter, compared to the consensus estimate of $685.24 million. During the same quarter in the previous year, the firm posted $1.56 EPS. The firm's revenue was up .4% on a year-over-year basis. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's payout ratio is 13.19%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on WST shares. Barclays started coverage on shares of West Pharmaceutical Services in a report on Tuesday, June 24th. They set an "equal weight" rating and a $245.00 target price for the company. Citigroup restated a "buy" rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Evercore ISI began coverage on shares of West Pharmaceutical Services in a report on Tuesday, March 18th. They issued an "outperform" rating and a $275.00 price objective for the company. Finally, Stephens upgraded shares of West Pharmaceutical Services to a "strong-buy" rating in a report on Monday, April 21st. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, West Pharmaceutical Services has an average rating of "Moderate Buy" and a consensus price target of $320.00.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.